Xofluza (baloxavir marboxil) is a small molecule pharmaceutical. Baloxavir marboxil was first approved as Xofluza on 2018-10-24. It is used to treat influenza a virus and influenza b virus in the USA. It has been approved in Europe to treat human influenza. Xofluza's patents are valid until 2037-08-09 (FDA).
|Common Name||Baloxavir marboxil|
|Indication||human influenza, influenza a virus, influenza b virus|